Abstract 181P
Background
There are no standardised, recognised regimens for third line treatment of advanced pancreatic cancer, with most clinicians using best supportive care in this scenario. Gemcitabine plus nab-paclitaxel and FOLFIRINOX are non-cross resistant regimens. This generates the hypothesis that patients who responded well in the first line setting to gemcitabine and nab-paclitaxel could respond again if rechallenged in the third line setting, after second line FOLFIRINOX.
Methods
A retrospective analysis was conducted via an electronic database from two of our institutions, of locally advanced or metastatic pancreatic adenocarcinoma patients who were treated with gemcitabine plus nab-paclitaxel both as a first line and third line chemotherapy regimen between January 2013 and July 2019. All patients had an ECOG performance status of 2 or less. Overall survival (OS) was estimated by the Kaplan-Meier method.
Results
We identified 30 patients in our analysis. 63% of the patients were female, with the median age of all patients at diagnosis being 67 (range, 38 – 82). 60% of the studied patients had locally advanced disease at diagnosis. Median OS from diagnosis was 39.0 months (95% CI, 34.0 – 66.0). Median OS from third-line re-initiation of gemcitabine plus nab-paclitaxel was 29.0 months (95% CI, 9.0 – 36.0).
Conclusions
Patient who maintain a good performance status after second line treatment present a management dilemma, as these patients are often reluctant to accept best supportive care when they feel well enough to tolerate another line of chemotherapy. The median OS (29 months) and age (67) is surprising, but probably represents the selection bias of patients who retain sufficient performance status to undergo third line therapy. Patients who have receive first line gemcitabine plus nab-paclitaxel, and second line FOLFIRINOX whilst maintaining good performance status, should be considered for re-treatment with gemcitabine plus nab-paclitaxel, as evidenced by our data from two of our institutions. Phase III studies would be highly beneficial to further investigate this as a potential standard of care for third-line treatment in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
St John of God Hospital Subiaco.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract